An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Medicare Coverage Significantly Expanded for the Eversense E3 CGM System On February 12, Ascensia Diabetes Care, announced that Medicare has significantly expanded access to the Eversense E3 CGM System with the implementation of Local Coverage Determinations providing access to implantable CGM...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia Last month, Spruce Biosciences, announced completion of enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH). Spruce Biosciences is...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Pilot Study Announced Exploring the Effect of Oral Testosterone Therapy (CIII testosterone undecanoate capsules) on Male Fertility On January 9, Marius Pharmaceuticals, announced it has initiated a pilot study to better understand the effect of oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate), on spermatogenesis...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Baseline Characteristics Reported from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH Spruce Biosciences, Inc., today reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH)....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency On December 19, Ascendis Pharma announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)... An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information.* New Clinical Data Point to Use of GlycoMark as Biomarker of SGLT-2 Diabetes Drug Effectiveness and Compliance Precision Diabetes, Inc. announces new studies that show that the GlycoMark blood test, which measures 1,5-anhydroglucitol, may be useful for evaluating short-term effectiveness and assessing...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves sNDA for Pediatric Achondroplasia Drug On October 20, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) to increase linear growth in pediatric patients with achondroplasia with open epiphyses (growth plates)....
